Recently, PARP1/2 inhibitors have been reported to be involved in cancer immunity via various mechanisms (Lee and Konstantinopoulos, 2019; Lampert et al., 2020; Lee and Konstantinopoulos, 2020). The gene discussed is PARP1; the disease is cancer.